Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Chugai

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Chugai's Japan sales performance.

Roche undercuts price of Bayer cancer drug after winning FDA approval

Roche undercuts price of Bayer cancer drug after winning FDA approval In Japan, where Rozlytrek won approval earlier this year, the drug came to market in conjunction with a companion diagnostic developed by Roche-subsidiary Foundation Medicine.

Tagrisso tops rival drugs on survival in first-line lung cancer

Tagrisso tops rival drugs on survival in first-line lung cancer the US, Europe and Japan and second-line use in China.

Bayer bags FDA nod for early prostate cancer drug darolutamide

Bayer bags FDA nod for early prostate cancer drug darolutamide Bayer says it has also submitted darolutamide in the EU, Japan, and additional countries around the world.

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi Entrectinib has just been approved in Japan, its first market, as Rozlytrek.

ACPs to lead gene therapies in haemophilia market growth

ACPs to lead gene therapies in haemophilia market growth GlobalData found that key opinion leaders in the eight major markets (the US, France, Germany, Italy, Spain, UK, Japan, and China) are highly optimistic about these therapies and agree that they

[ Previous 5 results ] 9 10 11 12 13 14 15 16 17 18 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics